- Home
- PRLD vs DRRX Comparison
PRLD vs DRRX Comparison
Compare PRLD & DRRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRLD
- DRRX
- Stock Information
- Founded
- PRLD 2016
- DRRX 1998
- Country
- PRLD United States
- DRRX United States
- Employees
- PRLD N/A
- DRRX N/A
- Industry
- PRLD Medicinal Chemicals and Botanical Products
- DRRX Biotechnology: Pharmaceutical Preparations
- Sector
- PRLD Health Care
- DRRX Health Care
- Exchange
- PRLD Nasdaq
- DRRX Nasdaq
- Market Cap
- PRLD 73.7M
- DRRX 44.4M
- IPO Year
- PRLD 2020
- DRRX 2000
- Fundamental
- Price
- PRLD $1.39
- DRRX $0.87
- Analyst Decision
- PRLD Strong Buy
- DRRX Buy
- Analyst Count
- PRLD 2
- DRRX 2
- Target Price
- PRLD $4.50
- DRRX $5.00
- AVG Volume (30 Days)
- PRLD 783.6K
- DRRX 162.5K
- Earning Date
- PRLD 02-13-2025
- DRRX 11-13-2024
- Dividend Yield
- PRLD N/A
- DRRX N/A
- EPS Growth
- PRLD N/A
- DRRX N/A
- EPS
- PRLD N/A
- DRRX N/A
- Revenue
- PRLD $3,000,000.00
- DRRX $8,594,000.00
- Revenue This Year
- PRLD N/A
- DRRX $54.32
- Revenue Next Year
- PRLD N/A
- DRRX N/A
- P/E Ratio
- PRLD N/A
- DRRX N/A
- Revenue Growth
- PRLD N/A
- DRRX N/A
- 52 Week Low
- PRLD $0.80
- DRRX $0.52
- 52 Week High
- PRLD $6.80
- DRRX $1.88
- Technical
- Relative Strength Index (RSI)
- PRLD 60.84
- DRRX 47.14
- Support Level
- PRLD $1.12
- DRRX $0.70
- Resistance Level
- PRLD $1.48
- DRRX $1.00
- Average True Range (ATR)
- PRLD 0.18
- DRRX 0.11
- MACD
- PRLD 0.05
- DRRX 0.01
- Stochastic Oscillator
- PRLD 74.78
- DRRX 53.13
About PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a clinical-stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.
About DRRX DURECT Corporation
Durect Corp is a biopharmaceutical company. It is engaged in the research, development, and manufacturing of pharmaceutical products. The company develops pharmaceutical products based on two categories which include new chemical entities and proprietary pharmaceutical programs. The company's pipeline products consist of DUR-928, POSIMIR, and others. Geographically, the company operates in the United States, Europe, Japan, and other countries, of which key revenue is derived from the Europe .